This site is intended for healthcare professionals
MS: learnings from the pandemic and innovations in patient care

Innovative research

Read time: 30 mins
Last updated:11th Nov 2020
Published:11th Nov 2020
Individualisation of treatment dosing adapts a treatment to a patients’ preferences and characteristics which, if successful, can improve the benefit risk profile of a therapy. Learn how innovative new research can allow healthcare professionals to tailor natalizumab treatment to specific patients and their needs.

A large number of disease-modifying treatments are now available to treat MS patients and with each of these treatments there is a unique benefit risk balance to consider. Innovative new research is now allowing treatments to be tailored to individual patients. This is improving patient care by addressing specific patient situations and helping to meet the individual needs of patients.

Presented by Professor Sven Meuth, this section of the symposium answers the question: What important new research should be considered when tailoring the use of natalizumab?

The NOVA study: Evaluating the efficacy of extended interval dosing

Professor Sven Meuth discusses the phase 3b NOVA study – an interventional study evaluating the efficacy, safety and tolerability of six-week EID of natalizumab compared to four-week SID in relapsing-remitting MS over 72 weeks.

Register free for full access to medthority.com

Onset of efficacy with natalizumab

A benefit/risk ratio should take into account the efficacy of a disease modifying therapy. In this video, Professor Sven Meuth introduces the body of evidence for natalizumab treatment outcomes and considers the clinical implications of some of the data obtained in the phase 2 efficacy and dose finding study of natalizumab.

Register free for full access to medthority.com

Introducing the concept of improvement in disability and investigating different EDSS functional systems

Professor Sven Meuth shares the results of the Tysabri Observational Program (TOP) study, for which most sites are in Europe1, which assessed the effect of natalizumab in real world use outcomes1. He focuses on the impact of natalizumab treatment over 10 years on disability, per the expanded disability status scale (EDSS), and delves into individual functional systems. He specifically looks at the effect of natalizumab on visual and bladder function from the AFFIRM Phase 3 and TRUST observational studies, respectively, given the importance these functions have on quality of life.

Register free for full access to medthority.com

Improvements in additional readout parameters and patient-centred outcomes

Professor Sven Meuth shares more data on new readout parameters not commonly used in clinical trials, like fatigue in the ENER-G study, and formal SDMT testing for cognitive function in the Swedish registry.

Register free for full access to medthority.com

Are improvements in disability more likely if natalizumab is used earlier vs later?

Returning to the European-based TOP study,1 Professor Sven Meuth answers the question – does the time between MS symptom onset and natalizumab treatment affect the percentage of treatment naïve patients showing EDSS improvement?

Register free for full access to medthority.com

How does a longer time before treatment affect newer measures of disability?

Professor Sven Meuth discusses a US-based analysis,2 derived from the MSPT3 using the TOUCH population in MS PATHS, which compared earlier use of natalizumab against later use of natalizumab in patients matched for the duration of treatment with natalizumab.

Register free for full access to medthority.com

Welcome: